AI-driven drug discovery platforms gain momentum with new funding and technology

The biotechnology sector is seeing increased activity in AI-driven drug discovery and clinical trial modeling. 3billion is set to present its Genetics-First AI Drug Discovery platform at BIO-Europe 2026 in Cologne, Germany. The company utilizes genomic data from over 120,000 patients and 600,000 clinical records to identify therapeutic targets, specifically focusing on genetic modifiers that may offer protective biological mechanisms against disease.

Separately, Atlas Bio has emerged from stealth mode with $13.2 million in funding from Creandum, First Momentum Ventures, and LEA Ventures. The company is developing a foundation AI model designed to conduct in silico clinical trials. This technology aims to predict patient responses to drugs before physical trials begin, helping biopharmaceutical companies evaluate different patient populations and indications to reduce the risk of failure in expensive clinical development stages.